Unspecific and mixed vulvovaginal infections characterized by vaginal discharge.
Conditions
Interventions
Trade Name: Geonistin vaginal tablets
Product Name: Geonistin vagianl tablets
Pharmaceutical Form: Vaginal tablet
Sponsors
PLIVA Hrvatska d.o.o.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Unspecific and mixed vulvovaginal infections characterized by vaginal discharge (pathological and/or unusual) and at least one additional sign/symptom. 2. Women of reproductive age, who are =18 years of age. 3. Lactobacillary grade =2 in vaginal exam. 4. According to investigator’s judgment the patients should receive local treatment only. 5. Signed informed consent. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 190 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: a. Trichomonas vaginalis infection (detected by wet preparation of vaginal smear or confirmed by OSOM® rapid test). b. Neisseria gonorrhea infection (clinically suspected). c. Chlamydia trachomatis infection (clinically suspected). d. Infection with Herpes simplex virus (clinically suspected). e. Patients with other vaginal or vulvar condition, which would confound the interpretation of clinical response. f. Women with cervical carcinoma. g. Women under treatment for cervical intraepithelial neoplasia (CIN). h. Recurrent BV (three or more episodes of BV in 12 months). i. Recurrent VVC (four or more VVC episodes in 12 months). j. Use of a topical or systemic antimicrobial treatment within 30 days before the study. k. On-going immunosuppressant treatment. l. On-going systemic antimicrobial therapy. m. On-going use of vaginal probiotics (oral and vaginal capsules, and all other form which helps regeneration of vaginal flora). n. Women currently menstruating or expecting menstruation within 1 week. o. Women using an intrauterine contraceptive device. p. Pregnancy (excluded by pregnancy urine test). q. Lactation. r. Patients who gave birth or underwent gynecological surgery within 2 months before the study. s. History of allergic reactions to nystatin or oxytetracycline or to excipients of the pharmaceutical product. t. Participation in another clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective of the study is to evaluate the clinical effectiveness of Geonistin vaginal tablets administered in empirical treatment of female adult patients with unspecific and mixed vulvovaginal infections characterized by vaginal discharge (pathological and/or unusual)..;Secondary Objective: The secondary objectives of the study are as follows: To assess systemic exposure to oxytetracycline following local treatment of vulvovaginal infections with Geonistin vaginal tablets; Cure rate according to the Nugent score (where applicable); Microbiology results (outcome); to evaluate safety of Geonistin vaginal tablets.;Primary end point(s): Clinical cure rate after 6 days of treatment.;Timepoint(s) of evaluation of this end point: Clinical effectiveness of 6 day treatment with Geonistin vaginal tablets in empirical treatment of vulvovaginal infections at day 13±2. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Trough steady-state serum concentrations of oxytetracycline, Cure rate according to the Nugent score (where applicable), Microbiological cure rate, Safety evaluation.;Timepoint(s) of evaluation of this end point: 30 days after the start of treatment. | — |
Countries
Croatia
Contacts
Public ContactManaging director
Clinres farmacija d.o.o.
Outcome results
None listed